Puma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 ... - PharmiWeb.com

04-10-2013 PharmiWeb.comComments (0)


Puma Biotechnology Inc. (NYSE:PBYI) a development stage biopharmaceutical company announced that it initiated a Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating ...

Read more on PharmiWeb.com

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top